StockData
KLA Corp logo

KLA Corp (KLAC) stock analysis

KLACNasdaqOptical Instruments & LensesFiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 15/3029% above fair value
$161.01+8.02 (+5.24%)

Close on Nov 11, 2026Market cap $209.79BP/E 40.3Yield 0.50%

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth4Performance5Health2Dividend4

Solid15 of 30 checks passed

KLA passes 15 of the 30 checks behind our score; 6 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
4/6
Past performance
5/6
Financial health
2/6
Dividend
4/6

What stands out

  • Return on equity over 15%

    Return on equity was 91.4% over the last twelve months and averaged 114% over five years.

  • Earnings grew over 5 years

    Net income grew 18.4% a year on average over the last five fiscal years.

  • EPS growing 10%+ a year

    Diluted EPS grew 14.9% a year over the last three fiscal years.

  • Earnings growth accelerating

    Net income grew 24.1% over the last twelve months, against a 5-year average of 18.4% a year.

What to watch

  • Margin of safety under 20%

    The price is 28.7% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $161.01 is above our fair value estimate of $125.09.

  • Revenue growing under 10% a year

    Revenue grew 9.0% a year over the last three fiscal years, short of the 10% we look for.

  • P/E above its 5-year median

    KLA's P/E of 40.3 is above its own 5-year median of 29.3.

Valuation0/6
  • P/E above its 5-year median

    KLA's P/E of 40.3 is above its own 5-year median of 29.3.

  • P/E above the industry

    KLA's P/E of 40.3 is above the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median of 36.5.

  • EV/EBITDA above its 5-year median

    KLA's EV/EBITDA of 30.6 is above its 5-year median of 21.0.

  • P/B above the industry

    KLA's price-to-book of 32.16 is above the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median of 3.17.

  • Trading above fair value

    The share price of $161.01 is above our fair value estimate of $125.09.

  • Margin of safety under 20%

    The price is 28.7% above fair value, so there is no margin of safety.

Growth4/6
  • Revenue growing under 10% a year

    Revenue grew 9.0% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing 10%+ a year

    Diluted EPS grew 14.9% a year over the last three fiscal years.

  • Earnings growth accelerating

    Net income grew 24.1% over the last twelve months, against a 5-year average of 18.4% a year.

  • Growing faster than the industry

    Revenue grew 15.8% over the last twelve months; the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median is 8.4%.

  • Guidance issued

    The latest outlook (second quarter of fiscal 2027 Total revenues, Oct 28, 2026) was issued for the first time, so it neither adds nor takes away points.

  • Gross margin improving

    Gross margin was 61.5% over the last twelve months, against 61.3% a year earlier.

Past performance5/6
  • Return on equity over 15%

    Return on equity was 91.4% over the last twelve months and averaged 114% over five years.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity above the industry

    KLA's return on equity of 91.4% is above the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median of 1.1%.

  • Earnings grew over 5 years

    Net income grew 18.4% a year on average over the last five fiscal years.

  • Net margin above its 5-year average

    Net margin was 36.2% over the last twelve months, against a 5-year average of 33.1%.

  • Net margin above the industry

    KLA's net margin of 36.2% is above the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median of -1.3%.

Financial health2/6
  • Debt level

    Needs debt and equity figures.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt coverage

    Needs operating cash flow.

  • Interest coverage

    Interest expense is not reported separately.

  • Short-term assets cover short-term debts

    Current assets are 2.76 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 12.21; above 3 is the safe zone and below 1.8 the distress zone.

Dividend4/6
  • Pays a dividend

    KLA paid dividends worth 0.5% of the share price over the last twelve months.

  • Yield below Treasuries

    The 0.5% yield is below the 4.4% on a 1-year Treasury.

  • Yield below the top quarter

    The top quarter of US dividend payers yield 3.8% or more; KLA yields 0.5%.

  • Dividend not cut

    The dividend per share has not fallen by more than 10% in any of the last 10 fiscal years.

  • Covered by earnings

    Dividends take 21.1% of net income.

  • Covered by free cash flow

    Dividends take 27.5% of free cash flow.

Scores of similar companies

Our estimate per share

$125.09

The share price is 29% above this estimate.

20%+ below
Near fair value
20%+ above
$161.01Price$125.09Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E32.9×29.3×36.5×$131.4553%
EV/EBITDA22.4×21.0×23.7×$117.8147%
Earnings powerleft out, too far from the others13.7% cost of equity––$19.68–
Fair value$125.09100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 29.3
  • Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median 36.5

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$2.10B
Value traded per 1% price move
$754.43M

Downside

High risk

Typical loss in a bad month
28.3%
Volatility (annualized)
64%
Sharpe ratio, 1 year
0.44
Beta to the S&P 500 (5Y)
1.77

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2012 to 2026

Gross margin

61.3%+1.4 pts over 5 years

Operating margin

–

Net margin

35.6%+5.5 pts over 5 years

See a number that looks wrong?